DBC's paradigm shifting sensors are a cost-effective method for the direct and continuous monitoring of medically important compounds, such as drugs and biomarkers.
Diagnostic Biochips, Inc (DBC) is a Maryland-based biosensor platform technology firm that is redefining measurement in medicine. DBC has developed a proprietary sensor "functionalization" process and a suite of biosensors that are set to transform the medical monitoring process. Its paradigm-shifting sensors are a cost-effective method for the direct and continuous monitoring of medically important compounds, such as drugs and biomarkers.
DBC is first targeting the large, rapidly-growing market for electrical and chemical detection in the pre-clinical research market where its technologies offer significant advantages to researchers seeking more productive, continuous monitoring of multiple, concurrent chemical responses. The larger market for DBC's chemical sensing technology is the pre-clinical drug development market in which pharmaceutical companies and CROs spend approximately $45B annually on the development of drug candidates.
DBC's biosensor technology will remove significant time and cost from this process by providing vastly improved, real-time data to these companies, allowing for shorter testing periods with fewer animals, faster rejection of unpromising drug candidates, and better and earlier prioritization of promising candidates. In the long term, DBC will partner with pharmaceutical companies to provide companion diagnostic sensors to drug candidates, and may also develop its own independent diagnostic sensor product. None of DBC's initial markets require FDA approval.